Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Neonatologists’ opinions about the ‘foreseeable risks’ in comparative effectiveness research: Results from an online survey

Subjects

Abstract

Objective:

To examine how neonatologists determine which risks require inclusion for informed consent per the ‘Common Rule’ and ‘Draft Guidance’ regulations in comparative effectiveness research (CER).

Study design:

Neonatologists active in research were invited to complete an online survey. Questions focused on clinical practices for treating hyperbilirubinemia in premature infants and about risk disclosure related to a hypothetical randomized trial.

Results:

Response rate was 57%. 43% were primarily researchers; 31% primarily clinicians. 69% had conducted CER. 81% thought hypothetical study enrollment was not riskier than receiving routine care. 76% labeled the study ‘minimal risk’ by comparing study risks to clinical care risks. Respondents would not currently disclose many of the treatment risks but would disclose more if the Draft Guidance were enacted into law.

Conclusion:

Findings suggest the Draft Guidance requires disclosure of more risks than does the Common Rule; applying either rule results in disclosure of more risks than in standard clinical care.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Macklin R, Shepherd L, Dreger A, Asch A, Baylis F, Brody H et al. The OHRP and SUPPORT—another view. N Engl J Med 2013; 369: e3.

    Article  Google Scholar 

  2. Wilfond BS, Magnus D, Antommaria AH, Appelbaum P, Aschner J, Barrington KJ et al. The OHRP and SUPPORT. N Engl J Med 2013; 368: e36.

    Article  Google Scholar 

  3. Department of Health and Human Services. Draft guidance on disclosing reasonably foreseeable risks in research evaluating standards of care. Federal Register 2014; 79 (206): 63629–63634.

    Google Scholar 

  4. Protection of Human Subjects, 45 C.F.R. § 46.111(a)(2) (2009). Available at http://www.hhs.gov/ohrp/regulations-and-policy/regulations/45-cfr-46/index.html Accessed on 2 June 2016.

  5. Maisels MJ, Watchko JF, Bhutani VK, Stevenson DK . An approach to the management of hyperbilirubinemia in the preterm infant less than 35 weeks of gestation. J Perinatol 2012; 32 (9): 660–664.

    Article  CAS  Google Scholar 

  6. National Institute for Health and Clinical Excellence. Neonatal Jaundice. National Institute for Health and Clinical Excellence, 2010. Available at www.nice.org.uk/CG98. Accessed on 20 January 2015.

  7. Magnus D, Wilfond BS . Research on medical practices and the ethics of disclosure. Pediatrics 2015; 135 (2): 208–210.

    Article  Google Scholar 

  8. Joffe S, Wertheimer A . Determining minimal risk for comparative effectiveness research. IRB 2014; 36 (3): 16–18.

    PubMed  Google Scholar 

  9. Cho MK, Magnus D, Constantine M, Lee SS, Kelley M, Alessi S et al. Attitudes toward risk and informed consent for research on medical practices: a cross-sectional survey. Ann Intern Med 2015; 162 (10): 690–696.

    Article  Google Scholar 

  10. Whicher D, Kass N, Faden R . Stakeholders’ views of alternatives to prospective Informed Consent for Minimal-Risk Pragmatic Comparative Effectiveness Trials. J Law Med Ethics 2015; 43 (2): 397–409.

    PubMed  Google Scholar 

Download references

Acknowledgements

We thank the neonatology researchers for their time in sharing their views with us. We thank NorthShore University HealthSystem Evanston Hospital for providing financial support for Dr Feltman’s subscription to the online survey tool used for this study. The funder had no direct role in the design and conduct of the study; collection, management, analysis and interpretation of the data; preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to D M Feltman.

Ethics declarations

Competing interests

Dr. Lantos receives royalties on five books he has written about bioethics. He receives occasional honoraria for lectures, including lectures about research ethics. Dr Feltman currently serves on her center’s Institutional Review Board, although did not at the time of data collection.

Additional information

Supplementary Information accompanies the paper on the Journal of Perinatology website .

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Feltman, D., Lantos, J. Neonatologists’ opinions about the ‘foreseeable risks’ in comparative effectiveness research: Results from an online survey. J Perinatol 37, 311–314 (2017). https://doi.org/10.1038/jp.2016.228

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/jp.2016.228

Search

Quick links